广州医科大学学报
廣州醫科大學學報
엄주의과대학학보
Academic Journal of Guangzhou Medical College
2014年
4期
143-146
,共4页
张继青%钟雷%葛宁%韩栋梁%李伟宏
張繼青%鐘雷%葛寧%韓棟樑%李偉宏
장계청%종뢰%갈저%한동량%리위굉
浆细胞瘤/综合治疗%髓外%多发性骨髓瘤
漿細胞瘤/綜閤治療%髓外%多髮性骨髓瘤
장세포류/종합치료%수외%다발성골수류
plasmacytoma/comprehensive treatment%extramedullary%multiple mydoma
目的:探讨髓外浆细胞瘤的临床特点诊疗手段。方法:对1995年1月至2013年12月在本科室收治的18例髓外浆细胞瘤进行回顾性分析,其中单纯放射治疗2例(11.7%),综合治疗15例(83.3%),单纯手术1例(5.6%)。结果:中位随访71个月(5~263个月),2例(11.7%)局部复发,3例(16.7%)转化为多发性骨髓瘤,单纯手术或放射治疗5年生存率为0,综合治疗的3、5、10年生存率分别为83.3%(15/18)、77.8%(7/9)、71.4%、(5/7)。结论:综合治疗髓外浆细胞瘤可获得良好的局部控制率和长期生存率,部分髓外浆细胞瘤可向多发性骨髓瘤转化,故需密切观察。
目的:探討髓外漿細胞瘤的臨床特點診療手段。方法:對1995年1月至2013年12月在本科室收治的18例髓外漿細胞瘤進行迴顧性分析,其中單純放射治療2例(11.7%),綜閤治療15例(83.3%),單純手術1例(5.6%)。結果:中位隨訪71箇月(5~263箇月),2例(11.7%)跼部複髮,3例(16.7%)轉化為多髮性骨髓瘤,單純手術或放射治療5年生存率為0,綜閤治療的3、5、10年生存率分彆為83.3%(15/18)、77.8%(7/9)、71.4%、(5/7)。結論:綜閤治療髓外漿細胞瘤可穫得良好的跼部控製率和長期生存率,部分髓外漿細胞瘤可嚮多髮性骨髓瘤轉化,故需密切觀察。
목적:탐토수외장세포류적림상특점진료수단。방법:대1995년1월지2013년12월재본과실수치적18례수외장세포류진행회고성분석,기중단순방사치료2례(11.7%),종합치료15례(83.3%),단순수술1례(5.6%)。결과:중위수방71개월(5~263개월),2례(11.7%)국부복발,3례(16.7%)전화위다발성골수류,단순수술혹방사치료5년생존솔위0,종합치료적3、5、10년생존솔분별위83.3%(15/18)、77.8%(7/9)、71.4%、(5/7)。결론:종합치료수외장세포류가획득량호적국부공제솔화장기생존솔,부분수외장세포류가향다발성골수류전화,고수밀절관찰。
Objective:To investigate the clinical feature and treatment of extramedullary plasmacytoma ( EMP ) . Methods:18 patients with extramedullary plasmacytoma admitted in our hospital from January 1995 to December 2013 were evaluated retrospectively, including 2 cases treated by radiotherapy alone ( 11. 7%) , 15 cases treated by comprehensive treatment ( 83. 3%) , and 1 case by surgery alone ( 5. 6%) . Results: During median follow-up of 71months (5-263moths), 2 (11.7%) developed local recurrences and 3 (16.7%) were converted to multiple mydoma. The survival rate of 5-years surgery alone or radiotherapy was 0. The overall 3, 5, and 10-years survival rates were 83.3% (15/18), 77.8% (7/9) and 71.4% (5/7) respectively. Conclusions:Comprehensive treatment on extramednllary plasmacytoma has good local control rate and long-term survival rate. Part of extramednllary plasmacytoma may convert to multiple myeloma and need close follow-up.